Parkinson’s treatments include drugs, surgery, rehabilitation, etc., and the general use of drugs at the beginning of the disease can be controlled and the ability to return to normal life. However, early drug treatment needs to weigh the pros and cons of improved recent symptoms against the risk of long-term motor complications.
The benefit is greater than the risk.
If Parkinson’s symptoms are more significant and the daily living and work requirements of patients are higher, the benefits of improved treatment are likely to outweigh the risks, which is a reasonable time to begin treatment. The initiation of treatment should, of course, also be based on the choice of drugs with lower long-term complications, such as dopamine receptor agonists, to avoid the early and heavy use of left-turned doba formulations.
While the long-term treatment of Parkinson’s patients by the left doba formulation may induce a series of motor complications, the main cause of this complication is the progress of the disease, and the pharmacological dose of the left doba does not cause neurotoxicity; it is also true that the significant benefits of the left doba formulation for Parkinson’s patients include significant improvement in symptoms, improved life-care and work capacity, and increased longevity. It is therefore recommended in the national and international guidelines for the treatment of Parkinson ‘ s disease that persons with visible symptoms in old age (especially those with slow movement and strong muscles) should begin treatment with a left-wing doba formulation in a timely manner.
Parkinson’s got a multi-drug option.
The current anti-Pakinson drugs, in addition to the left doba formulation, are also dopamine receptor agonists, monoamine oxidizers, gold-goldaneamines, Andan, etc., which are reasonably selected according to the patient ‘ s circumstances. For those with higher work and life requirements and younger Parkinson patients, non-left doppelga formulations are available to begin treatment in a timely manner, which is expected to reduce the risk of complications induced by left doppelga.
The treatment of Parkinson’s disease is not yet available at this stage, but is still primarily treatment for the disease. The treatment of the symptoms of Parkinson ‘ s disease should be based on the principles of safety, long-term effectiveness and stability. When determining when Parkinson’s disease begins to be treated, it is necessary to balance the effects of the treatment against the adverse effects, recent improvements against long-term complications, and to balance the benefits against the multiple factors of age, degree, type, functional requirements of the patient.
